Masayuki Hojo

Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2

Ryuta Uraki, Maki Kiso, Shun Iida et al. · Nature · 2022 · 288 citations · Full text

Immunology, Antiviral Drug Development, Virology +6

Inhaled Granulocyte/Macrophage–Colony Stimulating Factor as Therapy for Pulmonary Alveolar Proteinosis

Ryushi Tazawa, Bruce C. Trapnell, Yoshikazu Inoue et al. · American Journal of Respiratory and Critical Care Medicine · 2010 · 225 citations

Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19

Masaya Sugiyama, Noriko Kinoshita, Satoshi Ide et al. · Gene · 2020 · 104 citations · Full text

Disease Progression, Severe/critical Disease, Medicine +11

The Importance of Bacterial and Viral Infections Associated with Adult Asthma Exacerbations in Clinical Practice

Motoyasu Iikura, Masayuki Hojo, Rikiya Koketsu et al. · PLoS ONE · 2015 · 103 citations · Full text

Increased risk of nontuberculous mycobacterial infection in asthmatic patients using long‐term inhaled corticosteroid therapy

Masayuki Hojo, Motoyasu Iikura, Satoshi Hirano et al. · Respirology · 2011 · 94 citations